Gaborit, Benjamin
Vanhove, Bernard
Vibet, Marie-Anne
Le Thuaut, Aurélie
Lacombe, Karine
Dubee, Vincent
Ader, Florence
Ferre, Virginie
Vicaut, Eric
Orain, Jéremie
Le Bras, Morgane
Omnes, Anne
Berly, Laetitia
Jobert, Alexandra
Morineau-Le Houssine, Pascale
Botturi, Karine
Josien, Régis
Flet, Laurent
Degauque, Nicolas
Brouard, Sophie
Duvaux, Odile
Poinas, Alexandra
Raffi, François
Dailly, Eric
Guimard, Thomas
Braudeau, Cécile
Malvy, Denis
Faucher, Jean-François
Illes Hajnal, Gabriela
Vareil, Marc-Olivier
Roncato-Saberam, Mariam
Vacher, Laurent
Biron, Charlotte
Lefebvre, Maeva
Gallot, Géraldine
Le Turnier, Paul
Deschanvres, Colin
Lecomte, Raphael
Chauveau, Marie
Lecompte, Anne-sophie
Grégoire, Matthieu
Bellouard, Ronan
Deslandes, Guillaume
Ouazene, Zineb
Bollens, Diane
Chiarabani, Thibault
Krause-Le Garrec, Jessica
Becker, Agathe
Chauvelot, Pierre
Conrad, Anne
Ferry, Tristan
Miailhes, Patrick
Pouderoux, Cécile
Roux, Sandrine
Triffault-Fillit, Claire
,
Funding for this research was provided by:
Commissariat Général à l'Investissement
Article History
Received: 18 November 2020
Accepted: 13 February 2021
First Online: 9 March 2021
Declarations
:
: All patients participating in the study are given oral and written information about this trial and sign the informed consent form. This clinical study was submitted and approved by the ethic committee (Comité de Protection des Personnes Ouest VI - Committee for the Protection of Persons West VI) on 7 July 2020 under the reference: CPP Ouest 6 – CPP 1305 ME1.
: The InternalRef removed file contains the French informed consent form that the patient signs prior to the inclusion in the trial (Protocol: version 1.2, updated on 17 July 2020).
: FR has received consultancy fees from Gilead Sciences and Xenothera. OD and BV are employees and shareholders of Xenothera.